About Vicinitas
Vicinitas is a company based in San Francisco (United States) founded in 2022 by Dan Nomura. Vicinitas has raised $130 million across 2 funding rounds from investors including Andreessen Horowitz, Deerfield and Droia Ventures. Vicinitas offers products and services including DUBTAC Platform. Vicinitas operates in a competitive market with competitors including Accutar Biotechnology, Plexium, Lycia Therapeutics, Photys Therapeutics and Uvic Steratics, among others.
- Headquarter San Francisco, United States
- Founders Dan Nomura
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vicinitas Therapeutics.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$130 M (USD)
in 2 rounds
-
Latest Funding Round
$65 M (USD), Series A
Jul 29, 2022
-
Investors
Andreessen Horowitz
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vicinitas
Vicinitas offers a comprehensive portfolio of products and services, including DUBTAC Platform.
Platform restores degraded proteins to treat diseases effectively
Funding Insights of Vicinitas
Vicinitas has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vicinitas
Vicinitas has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Andreessen Horowitz, Deerfield and Droia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Droia Ventures is focused on investing in drug development companies.
|
Locked | Locked | Locked |
Investor details for Vicinitas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vicinitas
Investment portfolio details for Vicinitas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vicinitas
Detailed financials for Vicinitas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vicinitas Comparisons
Peer comparison for Vicinitas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vicinitas
Vicinitas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Plexium, Lycia Therapeutics, Photys Therapeutics and Uvic Steratics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-assisted tools for drug discovery are developed.
|
|
| Locked | Locked | Locked |
Integrated chemistry service provider
|
|
| Locked | Locked | Locked |
Protein degradation drugs are developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
Protein-based small molecules are developed to treat human diseases.
|
|
| Locked | Locked | Locked |
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
|
Detailed competitors of Vicinitas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vicinitas
Complete news archive for Vicinitas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vicinitas
Vicinitas was founded in 2022.
Vicinitas is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Vicinitas is a funded company, having raised a total of $130M across 2 funding rounds to date.
Vicinitas was founded in 2022 in San Francisco, United States, within the biotechnology sector. Therapeutics targeting cancer and monogenic diseases are developed through Deubiquituinase Targeting Chimeras (DUBTACs). These stabilizers prevent the degradation of specific proteins, thereby restoring their levels. Operations focus on protein stabilization mechanisms to address genetic disorders and oncology applications.
Vicinitas's top competitors include Plexium, Photys Therapeutics and Uvic Steratics.
Vicinitas offers DUBTAC Platform.
Vicinitas has 6 investors. Key investors include Andreessen Horowitz, Deerfield, Droia Ventures, Google Ventures, and The Mark Foundation for Cancer Research.